IP Library Granted Patent US 7,265,142
Granted Patent B2
US 7,265,142 · App. 10/643,699 · Granted Sep 4, 2007

Materials and methods for the treatment of hypertension and angina

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,265,142
App. No.
10/643,699
Granted
Sep 4, 2007
Kind
B2
Abstract

The subject invention provides useful and novel calcium channel blockers based upon mibefradil. The subject invention also provides methods for synthesizing the compounds of the invention. The invention also provides methods for the control or prevention of hypertension, angina pectoris, ischemia, arrhythmias, and cardiac insufficiency in a patient by administering a compound, or composition, of the invention to an individual in need of such treatment.

Claims (51)

1. A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:

wherein:

X=a bond, (CH 2 ) n , O, or O(CH 2 ) n ,

wherein n=1-6;

R 1 =C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 2 =F or COOR 5 ,

wherein R 5 is C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 3 =CH 3 or (CH 2 ) n —COOR 6 ,

wherein n=1-6 and R 6 is C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 4 =

R 15 =(CH 2 ) n COOR 16 ,

R 16 =C 1-6 alkyl, optionally substituted with OH or NH 2 , and

R 17 =not present or COOR 18 wherein R 18 is C 1-6 alkyl, optionally substituted with OH or NH 2 , and

wherein n=1-6.

2. A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has a formula selected from the group consisting of:

X=bond, OH 2 , or OCH 2

R=lower alkyl optionally substituted OH or NH 2 ;

R=lower alkyl optionally substituted by OH or NH 2 ;

n=1 to 3

R=lower alkyl optionally substituted by OH or NH 2 ;

n=1 to 3

R=lower alkyl optionally substituted by OH or NH 2 ; and

R=lower alkyl optionally substituted by OH or NH 2 .

3. The compound, according to claim 2 , wherein said compound has the following structure:

X=bond, CH 2 , or OCH 2

R=lower alkyl optionally substituted OH or NH 2 .

4. The compound, according to claim 2 , wherein said compound has the following structure:

R=lower alkyl optionally substituted by OH or NH 2 .

5. The compound, according to claim 2 , wherein said compound has the following structure:

n=1 to 3

R=lower alkyl optionally substituted by OH or NH 2 .

6. The compound, according to claim 2 , wherein said compound has the following structure:

n=1 to 3

R=lower alkyl optionally substituted by OH or NH 2 .

7. The compound, according to claim 2 , wherein said compound has the following structure:

R=lower alkyl optionally substituted by OH or NH 2 .

8. The method, according to claim 1 , wherein the patient is a human.

9. The method, according to claim 1 , wherein said method is used to treat a condition selected from the group consisting of hypertension, angina, ischemia, arrhythmia, congestive heart failure, and cardiac insufficiency.

10. A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:

wherein:

X=a bond, (CH 2 ) n , O, or O(CH 2 ) n ,

wherein n=1-6;

R 1 =C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 2 =F or COOR 5 ,

wherein R 5 is C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 3 =(CH 2 ) n —COOR 6 ,

wherein n=1-6 and R 6 is C 1-6 alkyl, optionally substituted with OH or NH 2 ;

R 4 =

R 15 =is H,

R 17 =not present or COOR 18 wherein R 18 is C 1-6 alkyl, optionally substituted with OH or NH 2 , and

wherein n=1-6.

Assignments (1)
SECURITY AGREEMENT Recorded Oct 18, 2010
From: ARYX THERAPEUTICS, INC.
To: AYER CAPITAL PARTNERS MASTER FUND, L.P.; MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; AYER CAPITAL PARTNERS KESTREL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC
Reel/Frame 025150/0379 →